DCR-MYC: Phase Ib/II started

Dicerna began an open-label, international Phase Ib/II trial to evaluate IV DCR-MYC on days 1 and 8 of a 21-day cycle in about 72 patients with locally advanced unresectable or metastatic HCC. The tri...